Access cutting-edge pulmonary arterial hypertension (pah) treatment through this phase 4 clinical trial at a research site in Columbus. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Columbus location
Preparing your pre-screening questions…
Access pulmonary arterial hypertension (pah) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pulmonary arterial hypertension (pah) treatment provided free
Check if you qualify for this pulmonary arterial hypertension (pah) clinical trial in Columbus, GA
No-Cost Study Care
Local to Columbus
Convenient for GA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs. Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks. The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.
Sponsor: Liquidia Technologies, Inc.
Yes, this clinical trial (NCT07759804) has an active research site in Columbus, GA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for pulmonary arterial hypertension (pah) treatment options in Columbus, GA, this clinical trial (NCT07759804) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Columbus research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced pulmonary arterial hypertension (pah) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all pulmonary arterial hypertension (pah) clinical trials near you to find additional studies recruiting in your area.
See all hypertension clinical trials recruiting in Columbus — not just this study.
Browse Hypertension Trials in Columbus →